You are here: Home > Prescription(RX) Drugs > H > Heparin Sodium In Dextrose (B. Braun Medical Inc.)

Name:Heparin Sodium In Dextrose
Manufacturer:B. Braun Medical Inc.
Category:Prescription Marketed Drugs


Heparin Sodium in 5% Dextrose Injection

HEPARIN SODIUM IN DEXTROSE - heparin sodium and dextrose injection 
B. Braun Medical Inc.

----------

Heparin Sodium in 5% Dextrose Injection

Do not admix with other drugs.

DESCRIPTION

Heparin Sodium in 5% Dextrose Injection is a sterile, nonpyrogenic solution prepared from heparin sodium (derived from porcine intestinal mucosa and standardized for use as an anticoagulant) and Hydrous Dextrose USP in Water for Injection USP. It is to be administered by intravenous injection. The potency is determined by a biological assay using a USP reference standard based on units of heparin activity per milligram.

Heparin is a heterogenous group of straight-chain anionic mucopolysaccharides, called glycosaminoglycans having anticoagulant properties. Although others may be present, the main sugars occurring in heparin are: (1) alpha-L-iduronic acid 2-sulfate, (2) 2-deoxy-2-sulfamino-alpha-D-glucose 6-sulfate, (3) beta-D-glucuronic acid, (4) 2-acetamido-2-deoxy-alpha-D-glucose, and (5) alpha-L-iduronic acid. These sugars are present in decreasing amounts, usually in the order (2) > (1) > (4) > (3) > (5), and are joined by glycosidic linkages, forming polymers of varying sizes. Heparin is strongly acidic because of its content of covalently linked sulfate and carboxylic acid groups. In heparin sodium, the acidic protons of the sulfate units are partially replaced by sodium ions. (See chart below for quantitative information.)

 Structure of Heparin Sodium (representative subunits):  Structure of Hydrous Dextrose USP:
 Chemical Structure  Chemical Structure
Composition – Each 100 mL Contains: Concentration of Electrolytes
(mEq/liter)
pH Calculated Osmolarity
mOsmol/liter
Solution Heparin Sodium USP Hydrous Dextrose USP Dibasic Sodium Phosphate Heptahydrate
USP
Citric Acid Anhydrous USP Sodium Phosphate
Symbol
Citrate
Sodium Metabisulfite NF (antioxidant) <0.07 g
Water for Injection USP qs
 Heparin Sodium 20,000 units in 5% Dextrose Injection  4,000 units  5 g  0.41 g  0.093 g  38  30  15  5.6
(4.5–7.0)
 315
 Heparin Sodium 25,000 units in 5% Dextrose Injection  5,000 units  5 g  0.41 g  0.093 g  38  30  15  5.6
(4.5–7.0)
 315
 Heparin Sodium 25,000 units in 5% Dextrose Injection  10,000 units  5 g  0.41 g  0.093 g  38  30  15  5.6
(4.5–7.0)
 315

The formulas of the inactive ingredients are:

Ingredients Molecular Formula Molecular Weight
Dibasic Sodium Phosphate Heptahydrate USP  Na2HPO4•7H2O  268.07
Citric Acid Anhydrous USP  CH2(COOH)C(OH)(COOH)CH2COOH  192.12

The EXCEL® Container is Latex-free; PVC-free; and DEHP-free.

The plastic container is made from a multilayered film specifically developed for parenteral drugs. It contains no plasticizers and exhibits virtually no leachables. The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.

The closure system has two ports; the one for the administration set has a tamper evident plastic protector. Refer to the Directions for Use of the container.

CLINICAL PHARMACOLOGY

Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Heparin acts at multiple sites in the normal coagulation system. Small amounts of heparin in combination with antithrombin III (heparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of heparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor.

Bleeding time is usually unaffected by heparin. Clotting time is prolonged by full therapeutic doses of heparin; in most cases it is not measurably affected by low doses of heparin.

Patients over 60 years of age, following similar doses of heparin, may have higher plasma levels of heparin and longer activated partial thromboplastin times (APTTs) compared with patients under 60 years of age.

Peak plasma levels of heparin are achieved 2–4 hours following subcutaneous administration, although there are considerable individual variations. Loglinear plots of heparin plasma concentrations with time for a wide range of dose levels are linear which suggests the absence of zero order processes. Liver and the reticuloendothelial system are the sites of biotransformation. The biphasic elimination curve, a rapidly declining alpha phase (t½ = 10 minutes) and after the age of 40 a slower beta phase, indicates uptake in organs. The absence of a relationship between anticoagulant half-life and concentration half-life may reflect factors such as protein binding of heparin.

Heparin does not have fibrinolytic activity; therefore, it will not lyse existing clots.

Dextrose provides a source of calories. Dextrose is readily metabolized, may decrease losses of body protein and nitrogen, promotes glycogen deposition and decreases or prevents ketosis if sufficient doses are provided.

INDICATIONS AND USAGE

Heparin Sodium in 5% Dextrose Injection is indicated as a continuous intravenous infusion following an initial intravenous therapeutic dose of heparin sodium.

Heparin Sodium Injection is indicated for anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; for prophylaxis and treatment of pulmonary embolism; in atrial fibrillation with embolization; for diagnosis and treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); for prevention of clotting in arterial and heart surgery; and in prophylaxis and treatment of peripheral arterial embolism.

CONTRAINDICATIONS

Heparin sodium should not be used in patients:

With severe thrombocytopenia;

In whom suitable blood coagulation tests – e.g., the whole blood clotting time, partial thromboplastin time, etc., – cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin);

With an uncontrollable active bleeding state (see WARNINGS), except when this is due to disseminated intravascular coagulation.

Solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.

WARNINGS

Heparin is not intended for intramuscular use.

Do not use Heparin Sodium in 5% Dextrose Injection as a "catheter lock flush" product.

Fatal Medication Errors

Heparin is supplied in a wide range of strengths. Fatal hemorrhages have occurred in infants and pediatric patients due to medication errors in which 1 mL Heparin Sodium Injection vials were confused with 1 mL "catheter lock flush" vials. Carefully examine all heparin products to ensure that the proper strength is selected for administration.

Hypersensitivity

Patients with documented hypersensitivity to heparin should be given the drug only in clearly life-threatening situations.

Hemorrhage

Hemorrhage can occur at virtually any site in patients receiving heparin. An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.

Heparin sodium should be used with extreme caution in disease states in which there is increased danger of hemorrhage. Some of the conditions in which increased danger of hemorrhage exists are:

Cardiovascular – Subacute bacterial endocarditis. Severe hypertension.

Surgical – During and immediately following (a) spinal tap or spinal anesthesia or (b) major surgery, especially involving the brain, spinal cord, or eye.

Hematologic – Conditions associated with increased bleeding tendencies, such as hemophilia, thrombocytopenia and some vascular purpuras.

Gastrointestinal – Ulcerative lesions and continuous tube drainage of the stomach or small intestine.

Other – Menstruation, liver disease with impaired hemostasis.

Coagulation Testing

When heparin sodium is administered in therapeutic amounts, its dosage should be regulated by frequent blood coagulation tests. If the coagulation test is unduly prolonged or if hemorrhage occurs, heparin should be discontinued promptly (see OVERDOSAGE).

Thrombocytopenia

Thrombocytopenia has been reported to occur in patients receiving heparin with a reported incidence of up to to 30%. Platelet counts should be obtained at baseline and periodically during heparin administration. Mild thrombocytopenia (count greater than 100,000/mm3) may remain stable or reverse even if heparin is continued. However, thrombocytopenia of any degree should be monitored closely. If the count falls below 100,000/mm3 or if recurrent thrombosis develops (see WARNINGS, Heparin-induced Thrombocytopenia and Heparin-induced Thrombocytopenia and Thrombosis), the heparin product should be discontinued, and, if necessary, an alternative anticoagulant administered.

Heparin-induced Thrombocytopenia (HIT) and Heparin-induced Thrombocytopenia and Thrombosis (HITT)

Heparin-induced Thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets. HIT may progress to the development of venous and arterial thromboses, a condition referred to as Heparin-induced Thrombocytopenia and Thrombosis (HITT). Thrombotic events may also be the initial presentation for HITT. These serious thromboembolic events include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal arterial thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death. Thrombocytopenia of any degree should be monitored closely. If the platelet count falls below 100,000/mm3 or if recurrent thrombosis develops, the heparin product should be promptly discontinued and alternative anticoagulants considered if patients require continued anticoagulation.

Delayed Onset of HIT and HITT

Heparin-induced Thrombocytopenia and Heparin-induced Thrombocytopenia and Thrombosis can occur up to several weeks after the discontinuation of heparin therapy. Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.

This product contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration.

Solutions containing dextrose without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility of agglomeration.

Excessive administration of potassium-free solutions may result in significant hypokalemia.

Because dosages of this drug are titrated to response (see DOSAGE AND ADMINISTRATION), no additives should be made to Heparin Sodium in 5% Dextrose Injection.

Use in Neonates

Carefully examine all heparin drug product containers to confirm choice of the correct strength prior to administration of the drug. Pediatric patients, including neonates, have died as a result of medication errors in which Heparin Sodium Injection vials have been confused with "catheter lock flush" vials. (See WARNINGS, Fatal Medication Errors.)

PRECAUTIONS

General

  1. Heparin-induced Thrombocytopenia (HIT) and Heparin-induced Thrombocytopenia and Thrombosis (HITT): (See WARNINGS .)
  2. Heparin Resistance:
    Increased resistance to heparin is frequently encountered in fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, myocardial infarction, cancer and in postsurgical patients.
  3. Increased Risk to Older Patients, Especially Women:
    A higher incidence of bleeding has been reported in patients, particularly women, over 60 years of age.

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance and electrolyte concentrations during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

Solutions containing dextrose should be used with caution in patients with overt or known subclinical diabetes mellitus, or carbohydrate intolerance for any reason.

Do not use plastic container in series connection.

If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result.

These solutions are intended for intravenous administration using sterile equipment. It is recommended that any unused heparin solution and intravenous administration apparatus be replaced at least once every 24 hours.

Use only if solution is clear and container and seals are intact.

Laboratory Tests

Periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy, regardless of the route of administration (see DOSAGE AND ADMINISTRATION).

Drug Interactions

Oral Anticoagulants

Heparin sodium may prolong the one-stage prothrombin time. Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.

Platelet Inhibitors

Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.

Other Interactions

Digitalis, tetracyclines, nicotine, antihistamines, or IV nitroglycerine may partially counteract the anticoagulant action of heparin sodium.

Drug/Laboratory Tests Interactions

Hyperaminotransferasemia

Significant elevations of aminotransferase AST (SGOT) and ALT (SGPT) levels have occurred in a high percentage of patients (and healthy subjects) who have received heparin. Since aminotransferase determinations are important in the differential diagnosis of myocardial infarction, liver disease and pulmonary emboli, rises that might be caused by drugs (like heparin) should be interpreted with caution.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term studies in animals to evaluate the carcinogenic potential, reproduction studies in animals to determine effects on fertility of males and females, and the studies to determine mutagenic potential have not been conducted with Heparin Sodium in 5% Dextrose Injection.

Pregnancy

Teratogenic Effects

Pregnancy Category C

Animal reproduction studies have not been conducted with Heparin Sodium in 5% Dextrose Injection. It is also not known whether Heparin Sodium in 5% Dextrose Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Heparin Sodium in 5% Dextrose Injection should be given to a pregnant woman only if clearly needed.

Nonteratogenic Effects

Heparin does not cross the placental barrier.

Nursing Mothers

Heparin is not excreted in human milk.

Pediatric Use

See DOSAGE AND ADMINISTRATION.

Geriatric Use

A higher incidence of bleeding has been reported in patients over 60 years of age, especially women (see PRECAUTIONS, General). Clinical studies indicate that lower doses of heparin may be indicated in these patients (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).

ADVERSE REACTIONS

Hemorrhage

Hemorrhage is the chief complication that may result from heparin therapy (see WARNINGS). An overly prolonged clotting time or minor bleeding during therapy can usually be controlled by withdrawing the drug (see OVERDOSAGE). It should be appreciated that gastrointestinal or urinary tract bleeding during anticoagulant therapy may indicate the presence of an underlying occult lesion. Bleeding can occur at any site but certain specific hemorrhagic complications may be difficult to detect:

  1. Adrenal hemorrhage, with resultant acute adrenal insufficiency, has occurred during anticoagulant therapy. Therefore, such treatment should be discontinued in patients who develop signs and symptoms of acute adrenal hemorrhage and insufficiency. Initiation of corrective therapy should not depend on laboratory confirmation of the diagnosis, since any delay in an acute situation may result in the patient's death.
     
  2. Ovarian (corpus luteum) hemorrhage developed in a number of women of reproductive age receiving short- or long-term anticoagulant therapy. This complication if unrecognized may be fatal.
     
  3. Retroperitoneal hemorrhage.

Thrombocytopenia, Heparin-induced Thrombocytopenia (HIT), Heparin-induced Thrombocytopenia and Thrombosis (HITT) and Delayed Onset of HIT and HITT

(See WARNINGS.)

Local Irritation

Local irritation, erythema, mild pain, hematoma or ulceration may follow deep subcutaneous (intrafat) injection of heparin sodium. These complications are much more common after intramuscular use, and such use is not recommended.

Hypersensitivity

Generalized hypersensitivity reactions have been reported, with chills, fever, and urticaria as the most usual manifestations, and asthma, rhinitis, lacrimation, headache, nausea and vomiting, and anaphylactoid reactions, including shock, occurring more rarely. Itching and burning, especially on the plantar site of the feet, may occur. (See WARNINGS.)

Certain episodes of painful, ischemic, and cyanosed limbs have in the past been attributed to allergic vasospastic reactions. Whether these are in fact identical to the thrombocytopenia associated complications remains to be determined.

Miscellaneous

Osteoporosis following long-term administration of high-doses of heparin, cutaneous necrosis after systemic administration, suppression of aldosterone synthesis, delayed transient alopecia, priapism, and rebound hyperlipemia on discontinuation of heparin sodium have also been reported.

Significant elevations of aminotransferase AST (SGOT) and ALT (SGPT) levels have occurred in a high percentage of patients (and healthy subjects) who have received heparin.

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

OVERDOSAGE

Symptoms

Bleeding is the chief sign of heparin overdosage. Nosebleeds, blood in urine or tarry stools may be noted as the first sign of bleeding. Easy bruising or petechial formations may precede frank bleeding.

Treatment

Neutralization of heparin effect.

When clinical circumstances (bleeding) require reversal of heparinization, protamine sulfate (1% solution) by slow infusion will neutralize heparin sodium. No more than 50 mg should be administered, very slowly, in any 10 minute period. Each mg of protamine sulfate neutralizes approximately 100 USP Heparin Units. The amount of protamine required decreases over time as heparin is metabolized. Although the metabolism of heparin is complex, it may, for the purpose of choosing a protamine dose, be assumed to have a half-life of about 1/2 hour after intravenous injection.

Administration of protamine sulfate can cause severe hypotensive and anaphylactoid reactions. Because fatal reactions often resembling anaphylaxis have been reported, the drug should be given only when resuscitation techniques and treatment of anaphylactoid shock are readily available.

For additional information the labeling of Protamine Sulfate Injection, USP products should be consulted.

DOSAGE AND ADMINISTRATION

Heparin Sodium in 5% Dextrose Injection is for intravenous use only. Do not use Heparin Sodium in 5% Dextrose Injection as a "catheter lock flush" product.

Confirm the choice of the correct heparin drug product and strength prior to administration of the drug to the patient (see WARNINGS, Fatal Medication Errors). Heparin sodium injection products must not be confused with "catheter lock flush" products.

Heparin Sodium is not effective by oral administration and Heparin Sodium in 5% Dextrose Injection should not be given orally.

This product should not be infused under pressure.

The dosage of heparin sodium should be adjusted according to the patient's coagulation test results. When heparin sodium is administered by continuous intravenous infusion, coagulation tests should be performed approximately every 4 hours during the early stages of therapy. Dosage is considered adequate when the activated partial thromboplastin time (APTT) is 1.5 to 2 times normal or when the whole blood clotting time is elevated approximately 2.5 to 3 times the control value.

Periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy, regardless of the route of administration.

When an oral anticoagulant of the coumarin or similar type is to be begun in patients already receiving heparin sodium, baseline and subsequent tests of prothrombin activity must be determined at a time when heparin activity is too low to affect the prothrombin time. This is about 5 hours after the last IV bolus and 24 hours after the last subcutaneous dose. If continuous IV heparin infusion is used, prothrombin time can usually be measured at any time.

In converting from heparin to an oral anticoagulant, the dose of the oral anticoagulant should be the usual initial amount and thereafter prothrombin time should be determined at the usual intervals. To ensure continuous anticoagulation, it is advisable to continue full heparin therapy for several days after the prothrombin time has reached the therapeutic range. Heparin therapy may then be discontinued without tapering.

Although dosage must be adjusted for the individual patient according to the results of suitable laboratory tests, the following dosage schedules may be used as guidelines:

Method of Administration Frequency Recommended Dose*
*
Based on 150-lb. (68-kg) patient.
   Initial dose  5,000 units by IV injection
 Continuous Intravenous infusion  Continuous  20,000 – 40,000 units/24 hours

Pediatric Use

Follow recommendations of appropriate pediatric reference texts. In general, the following dosage schedule may be used as a guideline:

Initial Dose: 50 units/kg (IV, drip).

Maintenance Dose: 20,000 units/m2/24 hours continuously.

Geriatric Use

Patients over 60 years of age may require lower doses of heparin. (See PRECAUTIONS.)

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED

Heparin Sodium in 5% Dextrose Injection is supplied sterile and nonpyrogenic in EXCEL® containers packaged 24 per case.

NDC Cat. No. Size
 Heparin Sodium 20,000 Units in 5% Dextrose Injection
   0264-9567-10  P5671  500 mL
 Heparin Sodium 25,000 Units in 5% Dextrose Injection
   0264-9577-10  P5771  500 mL
 Heparin Sodium 25,000 Units in 5% Dextrose Injection
   0264-9587-20  P5872  250 mL

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature (25°C); however, brief exposure up to 40°C does not adversely affect the product.

Storage in automated dispensing machines: Brief exposure up to 2 weeks to ultraviolet or fluorescent light does not adversely affect the product labeling legibility; prolonged exposure can cause fading of the red label. Rotate stock frequently.

Rx only

Revised: September 2010

EXCEL is a registered trademark of B. Braun Medical Inc.

Directions for Use of EXCEL® Container

Do not admix with other drugs.

Caution: Do not use plastic container in series connection.

To Open

Tear overwrap down at notch and remove solution container. Check for minute leaks by squeezing solution container firmly. If leaks are found, discard solution as sterility may be impaired.

 NOTE: Before use, perform the following checks:
   Inspect each container. Read the label. Ensure solution is the one ordered and is within the expiration date.
 
   Invert container and carefully inspect the solution in good light for cloudiness, haze, or particulate matter. Any container which is suspect should not be used.
 
   Use only if solution is clear and container and seals are intact.

Preparation for Administration

  1. Remove plastic protector from sterile set port at bottom of container.
  2. Attach administration set. Refer to complete directions accompanying set.

B. Braun Medical Inc.
Irvine, CA 92614-5895 USA
Made in USA

Y36-002-762   LD-239-1

PRINCIPAL DISPLAY PANEL - 500 mL Container Label

500 mL

EXCEL® CONTAINER

NDC 0264-9567-10
P5671

HEPARIN SODIUM
20,000 UNITS (40 UNITS/ML)
in 5% Dextrose Injection

Each 100 mL contains: Heparin Sodium USP
(porcine intestinal mucosa) 4,000 USP Heparin units
Hydrous Dextrose USP 5 g
Dibasic Sodium Phosphate•7H2O USP 0.41 g
Citric Acid Anhydrous USP 0.093 g
Sodium Metabisulfite NF (antioxidant) <0.07 g
Water for Injection USP qs

pH: 5.6 (4.5-7.0); Calc. Osmolarity: 315 mOsmol/liter

Electrolytes (mEq/liter):         Sodium 38
Phosphate (HPO =4) 30           Citrate 15

Warning: Do not admix with other drugs.

Sterile, nonpyrogenic. Single dose container.
Do not use in series connection.
For intravenous use only.
Use only if solution is clear and container
and seals are intact.

Recommended Storage:
Room temperature (25ºC). Avoid excessive heat.
Protect from freezing. See Package Insert.

Rx only
Latex-free; PVC-free; DEHP-free
EXCEL is a registered trademark of B. Braun Medical Inc.

B. Braun Medical Inc.
Irvine, CA USA 92614-5895

Made in USA       Y94-002-894

Do not remove overwrap until ready for use. After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard solution as sterility may be impaired.

Container Label P5671

PRINCIPAL DISPLAY PANEL - 500 mL Container Label

HEPARIN SODIUM
25,000 UNITS   50 UNITS/ML
in 5% Dextrose Injection

REF P5771
NDC 0264-9577-10

500 mL
EXCEL® CONTAINER

Each 100 mL contains: Heparin Sodium USP
(porcine intestinal mucosa) 5,000 USP Heparin units
Hydrous Dextrose USP 5 g
Dibasic Sodium Phosphate•7H2O USP 0.41 g
Citric Acid Anhydrous USP 0.093 g
Sodium Metabisulfite NF (antioxidant) <0.07 g
Water for Injection USP qs

pH: 5.6 (4.5-7.0)
Calc. Osmolarity: 315 mOsmol/liter

Electrolytes (mEq/liter):    Sodium 38
Phosphate (HPO= 4

) 30       Citrate 15
WARNING: Do not admix with other drugs.

Sterile, nonpyrogenic. Single dose container.

Do not use in series connection. For intravenous use only.
Use only if solution is clear and container and seals are
intact.

Recommended Storage:
Room temperature (25ºC). Avoid excessive heat.
Protect from freezing. See Package Insert.
Latex free, DEHP free and PVC free


Rx only
Other


EXCEL is a registered trademark of B. Braun Medical Inc.

B. Braun Medical Inc.
Irvine, CA 92614-5895 USA
Made in USA    LD-307-1    Y94-003-123

Do not remove overwrap until ready for use. After removing the overwrap, check for
minute leaks by squeezing container firmly. If leaks are found, discard solution as
sterility may be impaired.

EXP
LOT

500 mL Container Label P5771

PRINCIPAL DISPLAY PANEL - 250 mL Container Label

HEPARIN SODIUM
25,000 UNITS  100 UNITS/ML
in 5% Dextrose Injection

REF P5872
NDC 0264-9587-20

250 mL

EXCEL® CONTAINER

Each 100 mL contains:
Heparin Sodium USP (porcine intestinal
mucosa) 10,000 USP Heparin units;
Hydrous Dextrose USP 5 g; Dibasic Sodium
Phosphate•7H2O USP 0.41 g; Citric Acid
Anhydrous USP 0.093 g; Sodium
Metabisulfite NF (antioxidant) <0.07 g
Water for Injection USP qs

pH: 5.6 (4.5-7.0)
Calculated Osmolarity: 315 mOsmol/liter

Electrolytes (mEq/liter):   Sodium 38
Phosphate (HPO =4) 30;    Citrate 15

WARNING: Do not admix with other drugs.

Sterile, nonpyrogenic. Single dose container.
Do not use in series connection. For
intravenous use only. Use only if solution is
clear and container and seals are intact.

Recommended Storage: Room temperature
(25ºC). Avoid excessive heat. Protect from
freezing. See Package Insert.
Latex free, DEHP free and PVC free

     
Rx only
Other



EXCEL is a registered trademark of B. Braun Medical Inc.

B. Braun Medical Inc.
Irvine, CA 92614-5895 USA
Made in USA    

Y94-003-125   LD-309-1

Do not remove overwrap until ready for use. After
removing the overwrap, check for minute leaks
by squeezing container firmly. If leaks are found,
discard solution as sterility may be impaired.

EXP
LOT

250 mL Container Label


HEPARIN SODIUM IN DEXTROSE 
heparin sodium and dextrose injection
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0264-9567
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HEPARIN SODIUM (HEPARIN) HEPARIN SODIUM 4000 [USP'U]  in 100 mL
DEXTROSE (DEXTROSE) DEXTROSE 5 g  in 100 mL
Inactive Ingredients
Ingredient Name Strength
WATER  
SODIUM PHOSPHATE, DIBASIC 0.41 g  in 100 mL
ANHYDROUS CITRIC ACID 0.093 g  in 100 mL
SODIUM METABISULFITE 0.07 g  in 100 mL
Product Characteristics
Color      Score     
Shape Size
Flavor Imprint Code
Contains     
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0264-9567-10 24 CONTAINER (24 CONTAINER) in 1 CASE contains a CONTAINER
1 500 mL in 1 CONTAINER This package is contained within the CASE (0264-9567-10)

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA019952 09/16/2009

HEPARIN SODIUM IN DEXTROSE 
heparin sodium and dextrose injection
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0264-9577
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HEPARIN SODIUM (HEPARIN) HEPARIN SODIUM 5000 [USP'U]  in 100 mL
DEXTROSE (DEXTROSE) DEXTROSE 5 g  in 100 mL
Inactive Ingredients
Ingredient Name Strength
WATER  
SODIUM PHOSPHATE, DIBASIC 0.41 g  in 100 mL
ANHYDROUS CITRIC ACID 0.093 g  in 100 mL
SODIUM METABISULFITE 0.07 g  in 100 mL
Product Characteristics
Color      Score     
Shape Size
Flavor Imprint Code
Contains     
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0264-9577-10 24 CONTAINER (24 CONTAINER) in 1 CASE contains a CONTAINER
1 500 mL in 1 CONTAINER This package is contained within the CASE (0264-9577-10)

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA019952 09/16/2009

HEPARIN SODIUM IN DEXTROSE 
heparin sodium and dextrose injection
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0264-9587
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HEPARIN SODIUM (HEPARIN) HEPARIN SODIUM 10000 [USP'U]  in 100 mL
DEXTROSE (DEXTROSE) DEXTROSE 5 g  in 100 mL
Inactive Ingredients
Ingredient Name Strength
WATER  
SODIUM PHOSPHATE, DIBASIC 0.41 g  in 100 mL
ANHYDROUS CITRIC ACID 0.093 g  in 100 mL
SODIUM METABISULFITE 0.07 g  in 100 mL
Product Characteristics
Color      Score     
Shape Size
Flavor Imprint Code
Contains     
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0264-9587-20 24 CONTAINER (24 CONTAINER) in 1 CASE contains a CONTAINER
1 250 mL in 1 CONTAINER This package is contained within the CASE (0264-9587-20)

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA019952 09/16/2009

Labeler - B. Braun Medical Inc. (002397347)

Revised: 05/2011 B. Braun Medical Inc.



Source: http://dailymed.nlm.nih.gov
Reproduced with permission of U.S. National Library of Medicine


Copyright © 2017 Drugsdb.eu by Dionisios Fentas || Terms of Use

Loading

Prescription Marketed Drugs Alphabetically
A| B| C| D| E| F| G| H| I| J| K| L| M| N| O| P| Q| R| S| T| U| V| W| X| Y| Z| 0-9

Categories:
Prescription(RX) Drugs
Over-the-counter (OTC) Drugs
Homeopathic Drugs
Animal Drugs
Feedback